• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » BioElectronics president outlines four-part growth strategy

BioElectronics president outlines four-part growth strategy

August 4, 2014
CenterWatch Staff

In a letter to shareholders, Andrew J. Whelan, president of BioElectronics, emphasized a four-part growth strategy initiated in the last year. 

The first initiative is a global marketing program. Sales of ActiPatch Therapy products are steadily increasing in Boots, the dominant pharmacy chain in the U.K. The successful sales growth experience at Boots will facilitate and accelerate getting ActiPatch Therapy in more retail outlets around the world. Boots pharmacies are a strategic member of the Boots-Alliance, a global pharmacy-led health and well-being enterprise that includes Walgreens, the largest drugstore chain in the U.S.

The second initiative was in developing political and public support to induce the FDA to recognize BioElectronics’ therapeutic solutions. In February, FDA recommendations included Physical Medicine Devices; Reclassification and Renaming of Shortwave Diathermy for All Other Uses. By reclassifying this technology to reflect its safety and efficacy, the FDA appears to be making scientific evidence the determinant for additional market clearances, not out-dated categorizations. 

Once the FDA finally makes a ruling, the company plans to submit new 510(K) applications with extensive clinical data. With the new FDA approach to classification, the company is hopeful that it will get equivalent U.S. market clearances to those earned in Canada and the European Common Market.

The third initiative involved continuing clinical research to further substantiate clinical efficacy and establish more indications of use. Since the last company shareholder report, BioElectronics has successfully completed three clinical studies, some observational studies and collected a growing body of consumer testimonials and pain data. The double-blind, placebo-controlled studies were for osteoarthritis of the knee, long-term plantar fasciitis and lower back pain.

The fourth and final initiative focused on lowering costs of capital to finance expansion. There are a number of potential applications of BioElectronics’ underlying technology that has had to put on the back burner because of resource issues. One way to reduce the cost of capital is by partnering in specific key markets with companies that have established sales and marketing presence.

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing